Federal Register / Vol. 72, No. 59 / Wednesday, March 28, 2007 / Notices 14587 

The IHS anticipates an awards start 

date of August 1, 2007. 

VI. Award Administration Information 

1. Award Notices 

The Notice of award (NoA) will be 

initiated by the DGO and will be mailed 

via postal mail on or before June 22, 

2007 to each entity that is approved for 

funding under this announcement. The 

NoA will be signed by the Grants 

Management Officer and this is the 

authorizing document for which funds 

are dispersed to the approved entities. 

The NoA will serve as the official 

notification of the grant award and will 

reflect the amount of Federal funds 

awarded, the purpose of the grant, the 

terms and conditions of the award, the 

effective date of the award, and the 

budget/project period. The NoA is the 

legal binding document. Applicants 

who are approved but unfunded or 

disapproved based on their Objective 

Review score will receive a copy of the 

Executive Summary which identifies 

the weaknesses and strengths of the 

application submitted. 

2. Administrative Requirements 

Grants are administered in accordance 

with the following documents: 

• This Program Announcement. 

• 45 CFR Part 92, A Uniform 

Administrative Requirements for Grants 

and Cooperative Agreements to State, 

Local and Tribal Governments, or 45 

CFR Part 74, A Uniform Administrative 

Requirements for Awards to Institutions 

of Higher Education, Hospitals, Other 

Non Profit Organizations, and 

Commercial Organizations. 

• Grants Policy Guidance: HHS 

Grants Policy Statement, October 2006. 

• Cost Principles: OMB Circular A 87, 

State, Local, and Indian (title 2 Part 

225). 

• Administrative Requirements: OMB 

Circular A 122, A Non profit 

Organizations (title 2 Part 230). 

• Audit Requirements: OMB Circular 

A 133, Audits of States, Local 

Governments, and Non profit 

Organizations. 

3. Indirect Costs: This section applies 

to all grant recipients that request 

indirect costs in their application. In 

accordance with HHS Grants Policy 

Statement, Part II 27, IHS requires 

applicants to have a current indirect 

cost rate agreement in place prior to 

award. The rate agreement must be 

prepared in accordance with the 

applicable cost principles and guidance 

as provided by the cognizant agency or 

office. A current rate means the rate 

covering the applicable activities and 

the award budget period. If current rate 

is not on file with the awarding office, 

the award shall include funds for 

reimbursement of indirect costs. 

However, the indirect cost portion will 

remain restricted until the current rate 

is provided to DGO. 

Generally, indirect cost rates for IHS 

Tribal organization grantees are 

negotiated with the Division of Cost 

Allocation (DCA) at 

http://rates.psc.gov/, and indirect cost 

rates that are for IHS-funded, Federallyrecognized Tribes are negotiated with 

the Department of Interior. If your 

organization has questions regarding the 

indirect cost policy, please contact the 

DGO at (301) 443–5204. 

4. Reporting 

A. Progress Report. Program progress 

reports are required semi-annually. 

these reports will include a brief 

comparison of actual accomplishments 

to the goals established for the period, 

reasons for unmet accomplishments (if 

applicable), and other pertinent 

information as required. A final report 

must be submitted within 90 days of 

expiration of the budget/project period. 

B. Financial Status Report. Semiannual financial status reports must be 

submitted within 30 days of the end of 

the half year. Final financial status 

reports are due within 90 days of 

expiration of the budget/project period. 

Standard Form 269 (long form) will be 

used for financial reporting. 

C. Reports. Grantees are responsible 

and accountable for accurate reporting 

of the Progress Reports and Financial 

Status Reports which are due semi 

annually. Financial Status Reports (SF 

269) are due 90 days after each budget 

period and the final SF 269 must be 

verified from the grantee records on 

how the value was derived. Grantees 

must submit reports in a reasonable 

period of time. 

Failure to submit required reports 

within the time allowed may result in 

suspension or termination of an active 

grant, withholding of additional awards 

for the project, or other enforcement 

actions such as withholding of 

payments or converting to the 

reimbursement method of payment. 

Continued failure to submit required 

reports may result in one or both of the 

following: (1) The imposition of special 

award provisions; and (2) the non 

funding or non award of other eligible 

projects or activities. This applies 

whether the delinquency is attributable 

to the failure of the grantee organization 

or the individual responsible for 

preparation of the reports. 

5. Telecommunication for the hearing 

impaired is available at: TTY 301–443–

6394. 

VII. Agency Contacts 

For program information, contact Mrs. 

Patricia Lee-McCoy, Office of Public 

Health support, Division of Health 

Professions Support, 801 Thompson 

Avenue, TMP Suite 120, Rockville, 

Maryland 20852, (301) 443–6197, or Mr. 

Michael Berryhill, Office of Public 

Health Support, Division of Health 

Professions Support, 801 Thompson 

Avenue, TMP Suite 120, Rockville, 

Maryland 20852 (301) 443–6197. For 

grant application and business 

management information, contact Ms. 

Martha Redhouse, Division of Grants 

Operations, Indian Health Service, 801 

Thompson Avenue, TMP Suite 120, 

Rockville, Maryland 20852 (301) 443–

5204. 

Dated: March 22, 2007. 

Phyllis Eddy, 

Deputy Director for Management Operations, 

Indian Health Service. 

[FR Doc. 07–1498 Filed 3–27–07; 8:45 am] 

BILLING CODE 4165–16–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Proposed Collection; Comment 

Request; NCCAM Office of 

Communications and Public Liaison 

Communications Program Planning 

and Evaluation Research 

Summary: In compliance with the 

requirement of Section 3506(c)(2)(A) of 

the Paperwork Reduction Act of 1995, 

for opportunity for public comment on 

proposed data collection projects, the 

National Center for Complementary and 

Alternative Medicine (NCCAM), at the 

National Institutes of Health (NIH), will 

publish periodic summaries of proposed 

projects to be submitted to the Office of 

Management and Budget (OMB) for 

review and approval. 

Proposed Collection 

Title: NCCAM Office of 

Communications and Public Liaison 

Communications Program Planning and 

Evaluation Research. 

Type of Information Collection 

Request: Renewal. 

Need and Use of Information 

Collection: To carry out NCCAM’s 

legislative mandate to educate and 

disseminate information about 

complementary and alternative 

medicine (CAM) to a wide variety of 

audiences and organizations, the 

NCCAM Office of Communications and 

Public Liaison (OCPL) requests 

clearance to carry out (1) formative and 

(2) evaluative research of a variety of 


sroberts on PROD1PC70 with NOTICES
14588 Federal Register / Vol. 72, No. 59 / Wednesday, March 28, 2007 / Notices 

print and online materials, outreach 

activities, and messages to maximize 

their impact and usefulness. 

OCPL wishes to continue to carry out 

formative research to further understand 

the knowledge, attitudes, and behaviors 

of its core constituent groups: members 

of the general public, researchers, and 

providers of both conventional and 

CAM health care. In addition, it seeks to 

test newly formulated messages and 

identify barriers and impediments to the 

effective communication of those 

messages. With this audience research, 

OCPL will carry out pretesting of 

audience responses to NCCAM’s fact 

sheets, Web content, and other materials 

and messages. 

Clearance is also requested to 

continue to carry out evaluative 

research on existing materials and 

messages, as part of OCPL’s ongoing 

effort to develop a comprehensive 

program of testing and evaluation of all 

of its communications strategies. This 

evaluative research will include pilot 

testing of recently developed messages 

and information products such as fact 

sheets and brochures. It will also 

address the need to evaluate the 

processes by which new materials and 

messages were developed, the 

effectiveness of an outreach or the 

extent to which behaviors were changed 

by the message, and the impact of a 

message on health knowledge and 

behaviors. 

The tools to collect this information 

have been selected to minimize burden 

on NCCAM’s audiences, produce or 

refine messages that have the greatest 

potential to influence target audience 

attitudes and behavior in a positive 

manner, and to use Government 

resources efficiently. They may include 

individual in-depth interviews, focus 

group interviews, intercept interviews, 

self-administered questionnaires, 

gatekeeper reviews, and omnibus 

surveys. 

The data will enhance OCPL’s 

understanding of (1) the unique 

information needs and distinct healthinformation-seeking behaviors of its 

core constituencies, and (2) the 

segments within these constituencies 

with special information needs (for 

example, among the general public 

these segments include cancer patients, 

the chronically ill, minority and ethnic 

populations, the elderly, users of dietary 

supplements, and patients integrating 

complementary therapies with 

conventional medical treatments). 

Frequency of Response: On occasion. 

Affected Public: Individuals and 

households; non-profit institutions; 

Federal Government; State, Local, or 

Tribal Government. 

Type of Respondents: Adult patients; 

members of the public; health care 

professionals; organizational 

representations. The annual reporting 

burden is as follows. 

Estimated Number of Respondents: 

2,440; 

Estimated Number of Responses per 

Respondent: 1; 

Average Burden Hours per Response: 

0.29; and 

Estimated Total Burden Hours 

Requested: 2,137.5 for the 3-year 

clearance period (approximately 712.5 

hours annually). The annualized cost to 

respondents is estimated at $21,333. 

There are no Capital Costs, Operating 

Costs, or Maintenance Costs to report. 

Request for Comments: Written 

comments and/or suggestions from the 

public and affected agencies are invited 

on the following points: (1) Whether the 

proposed collection of information is 

necessary for the proper performance of 

the function of the agency, including 

whether the information will have 

practical utility; (2) The accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumption used; (3) 

Ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (4) Ways to minimize the 

burden of the collection of information 

on those who are to respond, including 

the use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology. 

For Further Information Contact: To 

request more information on the 

proposed project or to obtain a copy of 

the data collection plans and 

instruments, contact Christy Thomsen, 

Director, Office of Communications and 

Public Liaison, NCCAM, 31 Center 

Drive, Room 2B11, Bethesda, MD 20892, 

or fax your request to 301–402–4741, or 

e-mail thomsenc@mail.nih.gov. Ms. 

Thomsen can be contacted by telephone 

at 301–451–8876. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 60 days of the date of 

this publication. 

Dated: March 20, 2007. 

Christy Thomsen, 

Director, Office of Communications and 

Public Liaison, National Center for 

Complementary and Alternative Medicine, 

National Institutes of Health. 

[FR Doc. E7–5671 Filed 3–27–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

List of Drugs for Which Pediatric 

Studies Are Needed 

ACTION: Notice. 

SUMMARY: The National Institutes of 

Health (NIH) is providing notice of the 

‘‘Priority List of Drugs for Which 

Pediatric Studies Are Needed.’’ The NIH 

develops the list in consultation with 

the Food and Drug Administration 

(FDA) and pediatric experts, as 

mandated by the Best Pharmaceuticals 

for Children Act. This list prioritizes 

certain drugs that are most in need of 

study for use by children to ensure their 

safety and efficacy. The NIH will update 

the list at least annually until the Act 

expires on October 1, 2007. 

DATES: The list is effective upon 

publication. 

FOR FURTHER INFORMATION CONTACT: Dr. 

Perdita Taylor-Zapata, National Institute 

of Child Health and Human 

Development (NICHD), 6100 Executive 

Boulevard, Suite 4A–01, Bethesda, MD 

20892–7510, e-mail 

taylorpe@mail.nih.gov or 

BestPharmaceuticals@mail.nih.gov, 

telephone 301–496–9584 (not a toll-free 

number). 

SUPPLEMENTARY INFORMATION: The NIH 

is providing notice of the ‘‘List of Drugs 

for Which Pediatric Studies Are 

Needed,’’ as authorized under Section 3, 

Public Law 107–109 (42 U.S.C. 409I). 

On January 4, 2002, President Bush 

signed into law the Best 

Pharmaceuticals for Children Act 

(BPCA). The BPCA mandates that not 

later than one year after the date of 

enactment, the NIH in consultation with 

the FDA and experts in pediatric 

research shall develop, prioritize, and 

publish an annual list of certain 

approved drugs for which pediatric 

studies are needed. For inclusion on the 

list, an approved drug must meet the 

following criteria: (1) There is an 

approved application under section 

505(j) of the Federal Food, Drug, and 

Cosmetic Act (21 U.S.C. 355(j)); (2) there 

is a submitted application that could be 

approved under the criteria of section 

505(j) of the Federal Food, Drug, and 

Cosmetic Act; (3) there is no patent 

protection or market exclusivity 

protection under the Federal Food, 

Drug, and Cosmetic Act; or (4) there is 

a referral for inclusion on the list under 

section 505A(d)(4)(c); and additional 

studies are needed to assess the safety 

and effectiveness of the use of the drug 

in the pediatric population. The BPCA 


sroberts on PROD1PC70 with NOTICES